Herceptin Serious Infusion-Related AEs Hold At .25% Of Patients - Genentech
Executive Summary
The reporting rate for serious infusion-related adverse events for Genentech's breast cancer agent Herceptin (trastuzumab) has not changed from the .25% of treated patients reported in May, the company indicated after issuing a "Dear Doctor" letter Oct. 6 notifying healthcare professionals of updates to warnings in labeling.